Freshfields advises CVC Capital Partners IX on completion of its acquisition of the Therakos business from Mallinckrodt

Global law firm Freshfields has advised CVC Capital Partners (‘CVC’), on the completion of its previously announced carve-out acquisition of the Therakos business from global specialty pharma company Mallinckrodt. 

The investment in Therakos from CVC Capital Partners Fund IX will provide the resources and expertise to further develop the business and its services which improve the lives of patients.

Therakos is a fully integrated extracorporeal photopheresis (ECP) delivery system for autologous immunomodulatory therapy. With approvals for use in the U.S., Canada, Europe, Japan, Australia and Latin America, it is the platform-of-choice among healthcare providers and patients to treat a range of immune-related diseases.

The Freshfields team advising longstanding client CVC is led out of New York by Global Co-Head of Private Capital Neal J. Reenan, Head of US Private Capital Ian N. Bushner, and with support from Global Co-Head of Private Capital Charles Hayes in London.  

The Leveraged Finance team is led by Head of US Leveraged Finance Allison Liff. Specialist Life Sciences advice is being provided by Head of US Life Sciences Transactions Adam Golden.

The team includes partners Mena Kaplan (New York), Joe Soltis (New York), Emily Szasz (London), Lori Goodman (New York), and Bruce McCulloch (DC), counsel Michal Netanyahu (New York), senior associates Edmund Haxby (New York), Daniel Spencer (DC), Madeleine Tavcar (New York) Andrew Herman (New York) and Kelsey Avery (New York), and associates Connor Smith (New York), Allison Caramico (New York), Laura Zhu (New York), Meilun Chen (New York), Anup Nandra (New York), Matt Sieben (New York), Xavier Chitnavis (London), Meghan Arapakis (London), and Charlotte Bourne (London), and Tosin Owoka (New York).

UBS is serving as CVC’s financial advisor, together with Freshfields (legal counsel), PWC (financial) and Candesic (commercial).